Declaration of competing financial interests
From the following article:
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
William G. Kaelin Jr
Nature Reviews Cancer 8, 865-873 (November 2008)
doi:10.1038/nrc2502
Declaration: W.G.K. owns equity in, and consults for, Fibrogen, Inc. (South San Francisco, California, USA). Fibrogen, Inc. is developing drugs targeting prolyl hydroxylases.
